Position:Emeritus Director
PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240
Email:rury.holman@dtu.ox.ac.uk
ORCID ID0000-0002-1256-874X
Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.
Manuscript
Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL
Erenesto Maddaloni et al.
Diabetes Care 2025;48:235-242
Manuscript
The science of diabetes and a life of trials: The 2024 Banting Medal for Scientific Achievement Lecture
Rury R. Holman
Diabetes 2025;74:164-174
Manuscript
The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply
Amanda I Adler et al.
Lancet 2025;405:29
Manuscript
Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models
Helen A Dakin et al.
Med Decis Making 2025;45:45-59
Manuscript
Great Debate: Pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction
Nikolaus Marx et al.
European Heart Journal 2024;45:5117-5126
Manuscript
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92)
Beryl Lin et al.
Lancet Diabetes Endocrinol. 2024;12:904-914